As biosimilars sweep across the US and Europe, what’s next for this disruptive technology in oncology?
Biosimilars in the field of oncology are blazing a trail in Europe, with uptake and usage in the US lagging behind due to launch delays and intellectual property issues. There’s no doubt that the future for biosimilars is bright due to them delivering improved access to patients, whilst at the same time lowering costs and freeing up resources which can be spent on other treatments. But what do treating physicians think about how biosimilars in oncology are being used today? What are the key challenges and opportunities that exist for this disruptive technology, in terms of clinical development, approval, and switching? And how is the landscape likely to evolve in the future, both in terms of biosimilar prescribing and in which treatment settings these products are used?
Timelines, Key Issues Explored
FirstWord carried out in-depth quantitative research with 200 medical oncologists and haemato-oncologists in the US, France, Germany and the UK to understand the key issues, challenges, opportunities, concerns, and expectations of physicians in relation to current and future biosimilar usage in the oncology space . The key issues explored included:
- Current status of physician awareness, understanding and perceptions of biosimilars, including current and future reliability of information and educational sources
- At the national level, how physicians perceive the regulatory framework for biosimilars, and how this influences their biosimilar usage patterns
- Physician-level insights on key drivers and resistors of biosimilar usage, both now and in the future, plus insights on key market-shaping issues such as switching, interchangeability and pharmacy-level substitution
- Current and future prescribing patterns for key biosimilars, including filgrastim, rituximab, trastuzumab and bevacizumab
What to Expect from This Report
This physicians’ insight into current and future prescribing patterns for biosimilars in oncology, including supportive care, solid tumours and haematological cancers, makes important reading for pharma, not only for companies actively engaged in the development and commercialisation of biosimilars, but also for originator companies either experiencing, or about to experience, biosimilar competition. Find out what treating physicians are saying about biosimilars, what the key drivers and resistors are to their use today and in the future, and what challenges and opportunities remain. Download Biosimilars in Oncology (Physician Survey) and start deciphering what’s next for this critically important area. In this report you can expect to find:
- Quantitative insights on 17 key issues relating to current and future prescribing patterns for biosimilars in the US and Europe
- Issues explored via an online survey that included over 40 targeted questions put to each treating physician
- Their responses provided 36 critical insights, data for which is provided across 28 unique and never-seen-before charts
- When appropriate, key differences between US and European respondents are provided, thereby adding additional detailed insight
How Did We Do It?
We surveyed 200 medical oncologists and haemato-oncologists in the US, France, Germany and the UK (n=100 physicians in US, n=100 physicians in France, Germany, the UK). All respondents have been practicing for an average of 17 years, devote over 90% of their time to patient care and play an active prescribing role for biologics in supportive care, solid tumours and haematological cancers.
Why Buy Now?
This unique research will help you understand how treating physicians see the future oncology biosimilars therapy market evolving, and what key challenges and opportunities remain for this disruptive technology. In Biosimilars in Oncology (Physician Survey) you will also learn about some of the critical drivers and resistors to biosimilar usage, from the perspective of treating physicians, how things are likely to change in the future and and (where possible), how things differ between the US and Europe.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.